Abstract. Although mutations of APC, CTNNB1 (ß-catenin) and AXIN1 are rare in oral squamous cell carcinoma (OSCC), activation of the Wnt signaling pathway is thought to play an important role in oral carcinogenesis. In the present study, we examined the relationship between Wnt signaling and epigenetic alteration of the secreted frizzled-related protein (SFRP) genes in OSCC. We frequently detected loss of membrane localization of ß-catenin and its cytoplasmic or nuclear accumulation in OSCC cell lines, although these cell lines showed no APC or CTNNB1 (ß-catenin) mutations and no methylation of CDH1 (E-cadherin). By contrast, we frequently detected methylation of SFRP1 (7/17, 41%) SFRP2 (16/17, 94%) and SFRP5 (14/17, 82%) in a panel of OSCC cell lines, as well as in specimens of primary tumors collected from 44 OSCC patients (SFRP1, 10/42, 24%; SFRP2, 16/44, 36%; SFRP5, 7/43, 16%). We also observed that OSCC cell lines express various Wnt ligands, and that ectopic expression of SFRPs inhibited cancer cell proliferation. Our results confirm the frequent methylation and silencing of SFRP genes in OSCC, and suggest that their loss of function contributes to activation of Wnt signaling that leads to cell proliferation during oral carcinogenesis.
Introduction
Epidemiological studies have shown that oral squamous cell carcinoma (OSCC) is one of the most commonly occurring cancers of the head and neck (1) , and that alcohol and tobacco play key roles in its development (2, 3) . Although it has been suggested that OSCC arises through the accumulation of multiple genetic changes (4) (5) (6) , the precise molecular mechanism underlying its pathogenesis remains unclear. In addition to genetic changes, recent studies indicate that epigenetic silencing of cancer-related genes via DNA methylation also plays an important role in OSCC tumorigenesis (7, 8) . Genes involved in cell cycle regulation, apoptosis, DNA repair and cellular differentiation are all reportedly involved (9) (10) (11) (12) , though the precise role of DNA methylation in oral carcinogenesis is not fully understood.
Wnt ligands are secreted proteins that bind to transmembrane receptors in the Frizzled (Fz) family. During normal developmental processes, the resultant Wnt signaling plays essential roles in the regulation of cell proliferation, patterning and fate determination (13) . The binding of Wnt to Fz leads to dephosphorylation and stabilization of ß-catenin, which enables its translocation into the nucleus, where it interacts with members of the T-cell factor/lymphocyte enhancer factor (TCF/LEF) family of transcription factors to stimulate the expression of target genes. This signaling pathway is strongly implicated in tumorigenesis; indeed, the first mammalian Wnt isoform was identified based on its ability to promote mouse mammary tumorigenesis (14) . Moreover, activation of the canonical Wnt pathway caused by mutation of APC, AXIN1 and CTNNB1 (ß-catenin) has been observed in various human cancers (14, 15) . In OSCC, loss of heterozygosity at the APC locus is reported at frequencies ranging from 13% to 72.7% (16) (17) (18) (19) (20) , though mutations in APC, AXIN1 and CTNNB1 are rare (21, 22) . On the other hand, reduced levels of membrane-bound E-cadherin and/or ß-catenin and cytoplasmic accumulation of ß-catenin is often observed in OSCC, which indicates that Wnt signaling is activated in this disease (20) (21) (22) (23) (24) (25) and suggests that the activation is via an alternative pathway in OSCC.
There are several known classes of secreted Wnt antagonists, including the Cerberus, Wnt inhibitory factor 1 (WIF1), secreted frizzled-related protein (SFRP) and the Dickkopf (DKK) families (26) . The SFRP family is comprised of five glycoproteins identified as putative inhibitors of the Wnt signaling pathway (27) . SFRP proteins contain an N-terminal domain homologous to the cysteine-rich domain (CRD) of Fz and a C-terminal domain with some homology to netrin. This enables SFRPs to inhibit Wnt signaling by competing with Fz for Wnt binding via its CRD domain or by binding directly to Fz (27) .
We previously showed that SFRP1, -2 and -5 are frequently inactivated in colorectal cancer (CRC) and gastric cancer (GC), and that SFRPs suppress constitutive Wnt signaling when overexpressed in CRC and GC cells (28) (29) (30) . To date, methylation of SFRP genes and downregulation of their expression have been identified in bladder cancer (31) , prostate cancer (32), lung cancer (33) breast cancer (34) , and chronic lymphocytic leukemia (35) , which strongly suggests SFRPs function as tumor suppressor genes. Our aim in the present study was to characterize the epigenetic abnormalities of SFRP genes in OSCC and determine whether SFRPs function as tumor suppressors in OSCC.
Materials and methods
Cell lines and tissue specimens. DNA was prepared from 17 OSCC cell lines (HSC-2, HSC-3, HSC-4, Ca9-22, OSC-19, OSC-20, OSC-30, OSC-70, SAS, KOSC-3, Ho-1-u-1, Ho-1-N-1, HOC119, HOC621, MoN2, MoT and OM1) as described previously (8, 36) . To analyze restoration of SFRP gene expression, cells were treated with a DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-azadC; 2.0 μM) (Sigma, St. Louis, MO, USA) for 72 h, renewing the drug and medium every 24 h. In addition, 44 primary oral squamous cell carcinoma specimens from 44 patients were obtained from the Department of Oral Surgery, Sapporo Medical University Hospital. Adjacent non-tumorous oral tissue was also obtained from 33 of the 44 patients. Informed consent was obtained from all patients before the collection of the specimens. Genomic DNA was extracted using the standard phenol-chloroform procedure. Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and then treated with a DNA-free kit (Ambion, Austin, TX, USA). Total RNA from normal oral mucosa from a healthy individual was purchased from BioChain (Hayward, CA, USA).
Mutational analysis. Analysis of APC and CTNNB1 gene mutation was performed as described previously (37) . Briefly, codons 1140-1545 in exon 16 of APC were examined for mutations. Genomic DNA corresponding to this region was amplified by PCR using primers APC-F1 and APC-R1, after which the gel-purified PCR products were directly sequenced using an ABI3100 automated sequencer (Applied Biosystems, Foster City, CA, USA). Sequencing was performed in both the sense and antisense directions with the primers used for PCR and two pairs of internal primers (APC-F2, APC-F3, APC-R2 and APC-R3). For analysis of CTNNB1 mutation, exon 3 of the gene was amplified by PCR, after which the products were directly sequenced in both the sense and antisense directions with the primers used for PCR. PCR was run in a 50-μl volume containing 50 ng of genomic DNA, 1X Ex Taq Buffer (Takara, Otsu, Japan), 0.3 mM dNTP, 0.25 μM each primer and 1 U of Takara Ex Taq Hot Start Version (Takara). The PCR protocol entailed 5 min at 95˚C; 35 cycles of 1 min at 95˚C, 1 min at 55˚C and 1 min at 72˚C; and a 7-min final extension at 72˚C. Primer sequences are listed in Table I. RT-PCR. Single-stranded cDNA was prepared using SuperScript III reverse transcriptase (Invitrogen). The integrity of the cDNA was confirmed by also amplifying glyceraldehyde-3-phosphate dehydrogenase gene (GAPDH). PCR was run in a 50-μl volume containing 100 ng of cDNA, 1X Ex Taq Buffer (Takara), 0.3 mM dNTP, 0.25 μM each primer and 1 U of Takara Ex Taq Hot Start Version (Takara). The PCR protocol entailed 5 min at 95˚C; 35 cycles of 1 min at 95˚C, 1 min at 55˚C and 1 min at 72˚C; and a 7-min final extension at 72˚C. The primer sequences for RT-PCR analysis and PCR product sizes are listed in Table I .
Methylation analysis. Bisulfite treatment of genomic DNA was performed as described previously (30) . Methylation was analyzed using methylation-specific PCR (MSP) and bisulfite-sequencing, as described previously. PCR was run in a 25- ; and a 7-min final extension at 72˚C. The PCR protocol for bisulfite-sequencing entailed 5 min at 95˚C; 35 cycles of 1 min at 95˚C, 1 min at 60˚C and 1 min at 72˚C; and a 7-min final extension at 72˚C. Amplified bisulfite-sequencing PCR products were cloned into pCR2.1-TOPO vector (Invitrogen), and 10 clones from each sample were sequenced. The primer sequences and PCR product sizes are listed in Table I .
Western blotting. Western analysis was carried out as described previously (30) . Briefly, samples (20 μg) of cell lysate were subjected to 10% SDS-PAGE, after which the resolved proteins were transferred to Immobilon-P membranes (Millipore, Bedford, MA). The membranes were then blocked with 5% non-fat milk and 0.1% Tween-20 in TBS and probed with anti-ß-catenin (BD Biosciences, San Jose, CA, USA) or anti-GAPDH antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), after which the blots were visualized using enhanced chemiluminescence (Amersham, Arlington Heights, IL, USA).
Immunofluorescence microscopy. Cells cultured on chamber slides were washed with PBS and fixed with 4% paraformaldehyde, after which they were incubated with anti-ß-catenin monoclonal antibody (BD Biosciences), stained with anti-mouse IgG Alexa Fluor 488 (Invitrogen), and examined under an FV300-IX71 confocal laser scanning microscope (Olympus, Tokyo, Japan).
Colony formation assays. Cells (1x10 5 ) were plated in 6-well plates 24 h before transfection, and then transfected with 4 μg of one of the pcDNA3.1His-SFRP vectors or with empty vector using a Lipofectamine 2000 (Invitrogen) according to manufacturer's instructions. The SFRP vectors were prepared as described previously (29) . The cells were replated on 60-mm culture dishes 24 h after transfection and then selected for 14 days with 0.6 mg/ml G418, after which colonies were stained with Giemsa and counted using National Institute of Health IMAGE software.
Statistical analysis. Statistical analyses were carried out using SPSS software (version 11.0; SPSS Inc., Chicago, IL). Mann-Whitney U test and Fisher's exact test (2-sided) were used to evaluate the association between methylation of SFRP genes and clinicopathological features. Values of P<0.05 were considered significant.
Results

Analysis of ß-catenin expression in OSCC cell lines.
To investigate Wnt signaling in OSCC, we initially analyzed expression of ß-catenin in a set of OSCC cell lines. Western analysis using an anti-ß-catenin antibody revealed detectable levels of endogenous ß-catenin in all of the cell lines tested (Fig. 1A) . Immunocytochemical analysis of the cellular distribution of endogenous ß-catenin revealed cytoplasmic or nuclear accumulation of the protein in 14 of the 15 (93%) OSCC cell lines studied (Table II; representative Table I . Sequences of the primers used in this study and the expected product sizes. Fig. 1B ). Seven cell lines (47%) showed the presence of membrane-bound ß-catenin, but in many of those cells, nuclear or cytoplasmic localization was also observed (Table II; representative results in Fig. 1B) . These results confirmed activation of the Wnt signaling pathway in all but one of the OSCC cell lines tested, though the apparent degree of activation varied.
Analysis of APC, CTNNB1 and CDH1 in OSCC cells. To clarify the mechanism by which Wnt signaling is activated in OSCC cells, we next looked for mutations of APC and CTNNB1. This entailed examination of 17 OSCC cell lines for mutations in codons 1140-1545 of APC, which include the mutation cluster region (37) . It has been well documented that the majority of somatic APC mutations seen in CRC occur within this region; nonetheless, we detected no APC mutations in any of the OSCC cell lines studied (Table II) . We also looked for CTNNB1 mutations in these OSCC cell lines. Exon 3 was selected for sequencing because most mutations found in human cancers occur at the serine/ threonine residues in this exon. As with APC, however, we detected no CTNNB1 mutations in any of the OSCC cell lines. In addition, because loss of E-cadherin could be responsible for the reduced membrane localization of ß-catenin, we tested whether CDH1 was epigenetically silenced in the OSCC cell lines. MSP analysis revealed that CDH1 was unmethylated in all of the OSCC cell lines tested, and RT-PCR analysis confirmed that they expressed CDH1 mRNA (data not shown). Thus, we found no genetic or epigenetic alterations of APC, CTNNB1 or CDH1 in our panel of OSCC cell lines. Table II . Summary of ß-catenin staining and genetic/epigenetic analysis of Wnt-related genes in OSCC cell lines.
ß-catenin: C, cytoplasmic; M, membrane-bound; N, nuclear; ND, not done. Genetic/epigenetic analysis: WT, wild-type; M, methylated; U, unmethylated.
- 
Analysis of SFRP expression in OSCC cell lines.
We previously reported that three of the five SFRP genes (SFRP1, -2 and -5) were often methylated and silenced in CRC and GC cells (28, 30) . Therefore, in the present study we initially evaluated the expression status of SFRP1, -2 and -5 in our panel of OSCC cell lines. We found that SFRP1 mRNA was completely absent or its levels were significantly reduced in 7 of the 17 cell lines tested (HSC-2, HSC-3, HSC-4, Ca9-22, SAS, KOSC-3 and HOC119), and that treating the affected cells with the DNA methyltransferase inhibitor 5-aza-dC rapidly restored its expression ( Fig. 2A) . In addition, four cell lines showed some basal expression of SFRP1 mRNA that was also upregulated by 5-aza-dC (OSC-30, OSC-70, HOC621 and MoT) ( Fig. 2A) . SFRP2 mRNA was not seen or was barely detectable in all of the OSCC cell lines, and 5-aza-dC treatment restored its expression in many of these cells ( Fig. 2A) . SFRP5 mRNA was absent or its levels were reduced in 15 cell lines (HSC-2, HSC-4, Ca9-22, OSC-19, OSC-20, OSC-30, OSC-70, SAS, KOSC-3, Ho-1-N-1, HOC119, HOC621, MoN2, MoT and OM-1), and again 5-aza-dC enhanced expression in the affected cell lines (Fig. 2A) . In contrast to the cancer cells, all three SFRP genes were expressed in normal oral mucosa from a healthy individual ( Fig. 2A) . Taken together, these results strongly suggest that, in OSCC, SFRP genes are frequent targets of epigenetic silencing through methylation.
Analysis of SFRP methylation in OSCC cell lines.
We next used MSP to analyze the methylation status of SFRP genes. We observed SFRP1 methylation in 7 of the 17 (41%) OSCC cell lines tested ( Fig. 2B ; Table II) . SFRP2 methylation was detected in 16 (94%) cell lines, and SFRP5 methylation was detected in 14 (82%) ( Fig. 2B ; Table II ). In general, we observed a significant inverse correlation between methylation and expression of SFRP genes, but there were some exceptions. Although some methylation of SFRP5 was detected in HSC-3 and Ho-1-u-1 cells (Fig. 1B) , they showed a substantial basal expression of SFRP5 mRNA (Fig. 1A) , which was probably transcribed from the unmethylated allele. Conversely, RT-PCR analysis revealed that SFRP1 transcription was downregulated in four cell lines (OSC-30, OSC-70, HOC621 and MoT), although no methylation was observed in these cells (Fig. 2) . Likewise, HOC621 cells showed no methylation of SFRP2 or -5, but neither gene was transcribed (Fig. 2) . Despite the apparent absence of methylation, 5-aza-dC restored expression of both genes, suggesting some other epigenetic mechanism is responsible for their silencing in these cells ( Fig. 2A) . In contrast to OSCC cell lines, normal oral mucosal tissue did not show methylation of SFRP genes (Fig. 2B) .
To assess methylation status in more detail, we carried out bisulfite sequencing in selected cell lines and a sample of normal oral mucosa. Sequencing analysis revealed that the CpG islands of SFRP1, -2 and -5 are extensively methylated in Ca9-22 and KOSC-3 cells, whereas nearly all of the CpG sites were unmethylated in normal oral mucosa (Fig. 3) . Table III . SFRP methylation and clinicopathological features in primary OSCC.
-----------------------------------------------------------------------------------------------------
All SFRP At least one Total  44  32  10  28  16  36  7 
-----------------------------------------------------------------------
No. Unmethylated Methylated Ummethylated Methylated Unmethylated Methylated Unmethylated Methylated -------------------------------------------------------------------------------------------------------------------------------
Total sample number is 42 for SFRP1. b Total sample number is 43 for SFRP5.
-
Methylation of SFRP genes in primary OSCC. Given that SFRP genes were frequently methylated in cultured OSCC cell lines, we next attempted to determine the extent to which they are aberrantly methylated in primary OSCC tumors. When we used MSP to examine SFRP methylation in 44 OSCC specimens, we detected methylation of SFRP1 in 10 of 42 specimens (24%), SFRP2 in 16 of 44 (36%) and SFRP5 in 7 of 43 (16%) ( Table III; representative results in Fig. 4) . Two specimens were not informative for SFRP1 methylation and one was not informative for SFRP5 methylation due to insufficient PCR amplification. Among the 44 specimens tested, 22 (50%) showed methylation of at least one SFRP gene (Table III) . In general, methylation of SFRPs was tumor-specific or tumor-predominant, but weak methylation of SFRP genes was observed in some nontumorous oral mucosa from the OSCC patients (representative results in Fig. 4 ). This may have been caused by field defects. We next correlated the methylation status of each SFRP gene and the clinicopathological features of primary OSCCs (Table III) . We found no statistically significant correlations between methylation status and age, pT status, pN status, pM status, differentiation and tumor stage, smoking and alcohol consumption. We did, however, find that SFRP1 was methylated more frequently in male patients.
Suppression of OSCC cell proliferation by ectopic expression of SFRPs.
Our data suggest that loss of SFRP expression may be the primary cause of Wnt signal activation in OSCC cells. To investigate the consequences of silencing SFRP genes, we used RT-PCR to assess expression of Wnt ligands in OSCC cell lines. Although Wnt1 and -2 were not expressed in any of the OSCC cell lines, we found that all the cells expressed at least 6 of the 12 Wnt ligands tested (Fig. 5) . Notably, expression of Wnt3A, -6 and -7 was detected in many of the OSCC cell lines, whereas these genes were not expressed in normal oral mucosa (Fig. 5) . These results indicate that loss of SFRPs may enhance the effect of Wnt ligands in OSCC cells. We then investigated whether SFRPs could function as tumor suppressors by transfecting SFRP1, -2 or -5 into SAS and KOSC-3 cells, which otherwise do not express an SFRP, and carrying out colony formation assays (Fig. 6) . Notably, induction of any one of these SFRPs markedly suppressed cell proliferation, suggesting SFRPs act as tumor suppressors by negatively regulating Wnt signaling in OSCC.
Discussion
Compelling evidence suggests that activation of Wnt signaling plays an important role in carcinogenesis. ß-catenin is the center of the Wnt pathway, and its accumulation in the cytoplasm and nucleus is frequently observed in various cancers including CRC, GC, liver cancer and pancreatic cancer (14, 15) . Previous studies have also shown that APC, CTNNB1 and AXIN are frequently mutated in these cancers; for instance, APC is mutated in the germ line of individuals with familial adenomatous polyposis coli (FAP), and acquired mutations in APC, CTNNB1 or AXIN2 initiate the majority of sporadic CRCs (14, 15) .
Several groups have reported that the distribution of ß-catenin is different in OSCC cells than in normal mucosal cells. Whereas ß-catenin is localized exclusively to the membrane in normal oral mucosal epithelium (23), such membrane-bound ß-catenin is absent or diminished in OSCC, and there is a corresponding increase in cytoplasmic localization (20) (21) (22) (23) (24) (25) . We also observed that membranebound ß-catenin is reduced or absent in more than half of the OSCC cell lines we tested, and the majority of those cell lines showed cytoplasmic and/or nuclear accumulation of ß-catenin. Previous reports also demonstrated that aberrant expression of ß-catenin is inversely correlated with differentiation and is significantly associated with invasion and poor prognosis (23-25). Thus Wnt signaling appears to play a key role in oral carcinogenesis.
Many researchers have investigated genetic alteration of Wnt signal-related genes in OSCC. Loss of heterozygosity at the APC locus has been observed in OSCC at frequencies ranging from 13% (4/31) (20) (21) analyzed CTNNB1 and AXIN1 mutations in 30 primary OSCCs, but found no mutations in any of the samples. In the present study, we analyzed exon 3 of CTNNB1 and the mutation cluster region of APC in 17 OSCC cell lines, but found no mutations of either gene. Because aberrant expression of ß-catenin might be associated with the loss of E-cadherin protein, and epigenetic inactivation of CDH1 is frequently observed in various cancers including OSCC (38,39), we also analyzed the methylation and expression status of CDH1 in our panel of OSCC cell lines. However, CDH1 was neither methylated nor silenced in any of the OSCC lines studied. Taken together, these observations strongly suggest that activation of Wnt signaling is a common event in OSCC, one that is observed more often than genetic or epigenetic alterations of the key component genes.
We previously showed that epigenetic silencing of SFRP genes is one of the mechanisms by which Wnt signaling is activated in CRC and GC (29, 30) . Four SFRP family genes (SFRP1, -2, -4 and -5) are presently known to be targets of epigenetic silencing in human tumors (28) . Among them, SFRP1, -2 and -5 are methylated at particularly high frequencies in CRC and GC, and ectopic expression of these SFRPs suppresses both Wnt signaling and cell proliferation (28, 30) . Consistent with those findings, we observed that SFRP1, -2 and -5 were respectively methylated in 41, 94 and 82% of the OSCC cell lines tested; that expression of all three genes was lost or downregulated in the methylated cell lines; and that treatment with a DNA methyltransferase inhibitor, 5-aza-dC, restored their expression. Moreover, similar results were obtained with primary OSCCs.
To examine the effects of Wnt signaling in OSCC, we evaluated the expression status of the Wnt ligands in the OSCC cell lines. We previously found that at least 3 of the 11 known Wnt ligands are expressed CRC cell lines (29) , and even more were expressed in OSCC cell lines. As described above, we observed cytoplasmic/nuclear accumulation of ß-catenin in 14 of 15 OSCC cell lines in which multiple SFRP genes were methylated and silenced. Moreover, ectopic expression of SFRP suppressed OSCC cell proliferation in colony formation assays. Thus loss of SFRP expression appears to contribute to activation of Wnt signaling leading to cell proliferation in OSCC.
On the other hand, our findings obtained with a TOPFLASH reporter assay system indicate that TCF/LEF transcriptional activity is not upregulated in any of the OSCC cell lines tested, even when they show a loss of Wnt antagonist genes and cytoplasmic accumulation of ß-catenin (data not shown), which is consistent with our earlier findings in GC cells (30) . Although it is well known that mutation in APC, CTNNB1 and AXIN is rare in GC, we found that the majority of GC cells showed activation and nuclear accumulation of ß-catenin and methylation of multiple SFRP genes (30) . Among those GC cells, only a few cell lines in which APC or CTNNB1 was mutated showed significant upregulation of TCF/LEF transcriptional activity (30) . It may be that the TOPFLASH reporter assay is not sufficiently sensitive to detect weak or moderate activation of Wnt signaling.
In summary, we have shown that epigenetic silencing of multiple SFRP genes is a common event in OSCC. Methylation of SFRP genes is more frequently observed than genetic or epigenetic alterations of any other Wnt signalrelated gene in OSCC. Our data support the hypothesis that epigenetic silencing of SFRP genes is one of the major causes of Wnt signal activation in OSCC cells. In addition, our results not only shed light on a mechanism contributing to OSCC tumorigenesis, but also suggest that SFRP methylation may be useful molecular target for the diagnosis and treatment of OSCC.
